Logo image of BMRA

BIOMERICA INC (BMRA) Stock Fundamental Analysis

NASDAQ:BMRA - Nasdaq - US09061H3075 - Common Stock - Currency: USD

0.839  -0.05 (-5.73%)

After market: 0.82 -0.02 (-2.26%)

Fundamental Rating

2

Overall BMRA gets a fundamental rating of 2 out of 10. We evaluated BMRA against 190 industry peers in the Health Care Equipment & Supplies industry. While BMRA seems to be doing ok healthwise, there are quite some concerns on its profitability. BMRA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BMRA had negative earnings in the past year.
BMRA had a negative operating cash flow in the past year.
BMRA had negative earnings in each of the past 5 years.
BMRA had a negative operating cash flow in each of the past 5 years.
BMRA Yearly Net Income VS EBIT VS OCF VS FCFBMRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

Looking at the Return On Assets, with a value of -77.06%, BMRA is doing worse than 78.19% of the companies in the same industry.
BMRA has a Return On Equity of -109.60%. This is in the lower half of the industry: BMRA underperforms 65.96% of its industry peers.
Industry RankSector Rank
ROA -77.06%
ROE -109.6%
ROIC N/A
ROA(3y)-51.28%
ROA(5y)-46.48%
ROE(3y)-68.67%
ROE(5y)-61.12%
ROIC(3y)N/A
ROIC(5y)N/A
BMRA Yearly ROA, ROE, ROICBMRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

With a Gross Margin value of 10.71%, BMRA is not doing good in the industry: 82.45% of the companies in the same industry are doing better.
BMRA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for BMRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.97%
GM growth 5Y-14.58%
BMRA Yearly Profit, Operating, Gross MarginsBMRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

More info and screens

6

2. Health

2.1 Basic Checks

BMRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
BMRA has about the same amout of shares outstanding than it did 1 year ago.
BMRA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BMRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BMRA Yearly Shares OutstandingBMRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
BMRA Yearly Total Debt VS Total AssetsBMRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

BMRA has an Altman-Z score of -6.41. This is a bad value and indicates that BMRA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -6.41, BMRA is not doing good in the industry: 74.47% of the companies in the same industry are doing better.
There is no outstanding debt for BMRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.41
ROIC/WACCN/A
WACC9.06%
BMRA Yearly LT Debt VS Equity VS FCFBMRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

BMRA has a Current Ratio of 3.17. This indicates that BMRA is financially healthy and has no problem in meeting its short term obligations.
BMRA has a Current ratio of 3.17. This is comparable to the rest of the industry: BMRA outperforms 56.91% of its industry peers.
BMRA has a Quick Ratio of 2.22. This indicates that BMRA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BMRA (2.22) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.17
Quick Ratio 2.22
BMRA Yearly Current Assets VS Current LiabilitesBMRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.73% over the past year.
BMRA shows a small growth in Revenue. In the last year, the Revenue has grown by 1.44%.
The Revenue has been growing slightly by 0.81% on average over the past years.
EPS 1Y (TTM)14.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.06%
Revenue 1Y (TTM)1.44%
Revenue growth 3Y-9.06%
Revenue growth 5Y0.81%
Sales Q2Q%4.2%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMRA Yearly Revenue VS EstimatesBMRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
BMRA Yearly EPS VS EstimatesBMRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BMRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BMRA Price Earnings VS Forward Price EarningsBMRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BMRA Per share dataBMRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BMRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOMERICA INC

NASDAQ:BMRA (2/21/2025, 8:03:53 PM)

After market: 0.82 -0.02 (-2.26%)

0.839

-0.05 (-5.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-21 2025-01-21
Earnings (Next)04-10 2025-04-10
Inst Owners11.9%
Inst Owner Change-24.07%
Ins Owners10.82%
Ins Owner Change25.81%
Market Cap15.39M
Analysts85.71
Price TargetN/A
Short Float %1.56%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.76
P/FCF N/A
P/OCF N/A
P/B 3.01
P/tB 3.15
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0.3
BVpS0.28
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.06%
ROE -109.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.71%
FCFM N/A
ROA(3y)-51.28%
ROA(5y)-46.48%
ROE(3y)-68.67%
ROE(5y)-61.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.97%
GM growth 5Y-14.58%
F-Score3
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 85.88%
Cap/Sales 1.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.17
Quick Ratio 2.22
Altman-Z -6.41
F-Score3
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)97.33%
Cap/Depr(5y)119.71%
Cap/Sales(3y)1.51%
Cap/Sales(5y)2.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.06%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.44%
Revenue growth 3Y-9.06%
Revenue growth 5Y0.81%
Sales Q2Q%4.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.18%
OCF growth 3YN/A
OCF growth 5YN/A